Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a Kappa Receptor Agonist HSK21542 in Healthy Volunteers
NCT04110886 is registered in ClinicalTrials.gov with Sichuan Haisco Pharmaceutical Group Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a Kappa Receptor Agonist HSK21542 in Healthy Volunteers
- Lead sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 2, 2020
- Completion date
- January 5, 2021
- Enrollment
- 120 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.